Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study

Helicobacter pylori (Hp) drug resistant rate to clarithromycin (CLA) has increased to 20% to 50%, which cause concerns regarding its effectiveness in eradicating Hp, we aim to evaluate the cost-effectiveness of CLA-based versus furazolidone (FZD)-based quadruple therapy, and assess factors that affe...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Dong-Min, Yang, Tao-Tao, Chao, Shuai-Heng, Li, Ya-Xin, Zhou, Ying-Lei, Zhang, Hai-Hui, Lan, Ling, Zhang, Yu-Wei, Wang, Xue-Mei, Zhang, Yan-Rui, Li, Jian, Ding, Song-Ze
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380699/
https://www.ncbi.nlm.nih.gov/pubmed/30732192
http://dx.doi.org/10.1097/MD.0000000000014408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380699/
https://www.ncbi.nlm.nih.gov/pubmed/30732192
http://dx.doi.org/10.1097/MD.0000000000014408

Ejemplares similares